Department of Public Health, School of Medicine, Yokohama City University, Yokohama, Japan.
Department of General Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Cancer Sci. 2024 Feb;115(2):672-681. doi: 10.1111/cas.15975. Epub 2024 Jan 7.
The Japan Diabetes Society and the Japan Cancer Association launched a joint committee and published their "First Joint Committee Report on Diabetes and Cancer" in 2013, compiling recommendations for physicians and health-care providers as well as for the general population. In 2016, the "Second Joint Committee Report on Diabetes and Cancer" summarized the current evidence on glycemic control and cancer risk in patients with diabetes. The current "Third Joint Committee Report on Diabetes and Cancer", for which the joint committee also enlisted the assistance of the Japanese Society of Clinical Oncology and the Japanese Society of Medical Oncology, reports on the results from the questionnaire survey, "Diabetes Management in Patients Receiving Cancer Therapy," which targeted oncologists responsible for cancer management and diabetologists in charge of glycemic control in cancer patients. The results of the current survey indicated that there is a general consensus among oncologists and diabetologists with regard to the need for guidelines on glycemic control goals, the relevance of glycemic control, and glycemic control during cancer therapy in cancer patients.
日本糖尿病学会和日本癌症协会于 2013 年成立了一个联合委员会,并发布了他们的“糖尿病与癌症第一联合委员会报告”,为医生、医疗保健提供者以及普通民众编写了相关建议。2016 年,“糖尿病与癌症第二联合委员会报告”总结了目前关于糖尿病患者血糖控制与癌症风险的证据。目前的“糖尿病与癌症第三联合委员会报告”,联合委员会还得到了日本临床肿瘤学会和日本肿瘤内科学会的协助,报告了针对负责癌症管理的肿瘤学家和负责癌症患者血糖控制的糖尿病学家的问卷调查“癌症治疗患者的糖尿病管理”的结果。目前的调查结果表明,肿瘤学家和糖尿病学家普遍认为需要制定关于血糖控制目标、血糖控制相关性以及癌症治疗期间血糖控制的指南。